Citations

Clear

4847 citation(s) found for "Yu, Eric".

Pouch excision: indications and outcomes
Dattani, Sheev, Dozois, Eric J. , Moncrief, Sara, Pembérton, John H., Mathis, Kellie L. , Lightner, Amy L.

Mayo Clinic

Colorectal Disease | April 7, 2017 | Volume: 19 | Issue: 10 | Pages: 912-916

10.1111/codi.13673 | PMID 28387059 Get It

AbstractAimRestorative proctocolectomy with ileal‐pouch anal anastomosis is the procedure of choice for ulcerative colitis. Unfortunately, up to 10% of pouches will fail, requiring either reconstruction or excision. While several series have reported on the aetiology of pouch failure, no study to date has focused on the postoperative complications associated with pouch excision.MethodsPatients who had excision of ileoanal reservoir with ileostomy (CPT code 45136) were included. Data abstracted included preoperative, operative and postoperative variables. A Kaplan–Meier curve of pouch survival was performed.ResultsIn all, 147 patients met the inclusion criteria for the study. The median age of patients was 47 years (73 women), and 132 had a diagnosis of ulcerative colitis at the time of colectomy. The most common indications for pouch excision were sepsis (n = 46; 31%) and Crohn's disease (n = 37; 25%). 84 (57%) patients experienced short‐term (< 30 days) postoperative complications, the most common of which was a surgical site infection (n = 32; 21%); 55 (37%) patients had long‐term complications (> 30 days) postoperatively, the most common of which was a return to the operating room (n = 19; 13%) largely for perineal wounds. Thirty‐day mortality was zero. 4.8%, 47.6%, 65.3% and 84.4% of patients had undergone pouch excision by 1, 5, 10 and 20 years from the time of pouch construction, respectively.ConclusionsPouch excision has a high rate of both short‐ and long‐term postoperative complications. Patients should be appropriately counselled to set expectations accordingly. In view of these findings we suggest that this operation should ideally be performed at a high volume centre with the availability of a multidisciplinary surgical team.
Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene
Valla, Jon, Yaari, R. , Wolf, Andrew B. , Kusne, Yael , Beach, Thomas G. , Roher, Alex E., Corneveaux, Jason J., Huentelman, Matthew J. , Caselli, Richard J. , Reiman, Eric M.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 22 | Issue: 1 | Pages: 307-313

10.3233/jad-2010-100129 | PMID 20847408 Get It

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
Strauss, Gary M., Maddaus, Michael A. , Johnstone, David W., Watson, Dorothy, Sugarbaker, David J., Schilsky, Richard L. , Green, M. R., Herndon, Justine , Johnson, Eric A.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 7019-7019

10.1200/jco.2004.22.90140.7019 Get It

SWOG 99–16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)
Petrylak, D. P., Tangen, C., Lara, P. N. , Jones, J., Talpin, M. E., Burch, P., Greene, G., Crawford, E. D., Hussain, Maha , Burch, P. A., Small, Eric J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3-3

10.1200/jco.2004.22.90140.3 Get It

A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma
Richards, Jon, Bedikian, A. Y., González, René , Whitman, Eric D. , Morse, Mark A. , Amatruda, Thomas, Galanis, E., Atkins, Michael B. , Lutzky, Jose

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 7509-7509

10.1200/jco.2004.22.90140.7509 Get It

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916
Pauler, Donna K., Taplin, Mary Ellen, Burch, Patrick A. , Greene, Graham, Lara, Primo N. , Petrylak, Daniel P. , Crawford, Emily D. , Tangen, Catherine M. , Hussain, Maha , Small, Eric J. , Greene, G. F.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 4505-4505

10.1200/jco.2004.22.90140.4505 Get It

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)
Hedrick, Eric, Hurwitz, Herbert I. , Sarkar, Somnath , Griffing, S., Novotny, William , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3517-3517

10.1200/jco.2004.22.90140.3517 Get It

Management of Recurrent and Metastatic HPV‐Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery
Sims, John R. , Abel, Kathryn M. Van , Martin, Eliot J., Lohse, Christine M. , Olsen, Kerry D., Moore, Eric J. , Van Abel, Kathryn, Price, Daniel L. , Van Abel, Kathryn M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 4, 2017 | Volume: 157 | Issue: 1 | Pages: 69-76

10.1177/0194599817696304 | PMID 28374634 Get It

ObjectiveTo describe management and oncologic outcomes for patients who develop locoregional recurrence (LRR) or distant metastasis (DM) following transoral robotic surgery for human papilloma virus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC).Study DesignCase series with chart review.SettingTertiary care referral center.Subjects and MethodsA total of 286 patients with HPV‐positive OPSCC who underwent transoral robotic surgery–based treatment from May 2007 to May 2015.ResultsOf 286 patients (12.2%), 35 met inclusion criteria. Of these, 19 experienced an LRR and 16 developed a DM; 2 patients with LRR subsequently developed DM. In those patients with an LRR, 79% had T1/T2 tumors, and 47% had N0/N1 nodal disease, compared with 75% and 6% in the DM group, respectively. The median time to LRR or DM was 0.6 years (interquartile range [IQR], 0.4‐1.0) and 1.8 years (IQR, 1.0‐2.1), respectively. Salvage treatment with intent to cure was attempted in 23 patients (16 LRR, 7 DM). The median time from LRR or DM to last follow‐up for the 18 patients who were still alive after salvage was 1.9 years (IQR, 0.4‐3.8; range, 7 days–6.2 years). Estimated cancer‐specific survival rates at 3 years following intent‐to‐cure treatment were 63% (95% CI, 39‐100; number still at risk, 5) in the LRR group and 100% (95% CI, 100‐100; number still at risk, 2) in the DM group.ConclusionOverall, LRR and DM for HPV‐positive OPSCC following transoral robotic surgery–based therapy are infrequent. In our subset of patients who underwent intent‐to‐cure treatment, cancer‐specific survival rates were favorable. Therefore, aggressive salvage treatment for LRR and DM for HPV‐positive OPSCC should be recommended for appropriate candidates.
Whole exome sequencing of a patient with suspected mitochondrial myopathy reveals novel compound heterozygous variants in RYR 1
Blackburn, Patrick R. , Selcen, Duygu , Gass, Jennifer , Jackson, Jessica L. , Macklin, Sarah , Cousin, Margot A. , Boczek, Nicole J. , Klee, Eric W. , Dimberg, Elliot L., Kennelly, Kathleen D., Gass, Jennifer M , Atwal, Paldeep S , Cousin, Margot A

Mayo Clinic

Molecular Genetics & Genomic Medicine | March 31, 2017 | Volume: 5 | Issue: 3 | Pages: 295-302

10.1002/mgg3.280 | PMID 28547000 Get It

Abstract Background Pathogenic variants in ryanodine receptor 1 ( RYR 1, MIM # 180901) are the cause of congenital myopathy with fiber‐type disproportion, malignant hyperthermia susceptibility type 1, central core disease of muscle, multiminicore disease and other congenital myopathies. Methods We present a patient with global developmental delay, hypotonia, myopathy, joint hypermobility, and multiple other systemic complaints that were noted early in life. Later she was found to have multiple bone deformities involving her spine, with severe scoliosis that was corrected surgically. She was also diagnosed with ophthalmoplegia, chronic hypercapnic respiratory failure, and hypertension. At 22 years of age she presented to the genetics clinic with a diagnosis of mitochondrial myopathy and underwent whole exome sequencing ( WES ). Results Whole exome sequencing revealed two novel compound heterozygous variants in RYR 1 (c.7060_7062del, p.Val2354del and c.4485_4500del, p.Tyr1495X). Conclusion Review of her clinical, pathologic, and genetic findings pointed to a diagnosis of a congenital myopathy with fiber‐type disproportion.